ArticleBMC nephrology2026
Acute kidney injury and mortality in cirrhosis: a nationwide analysis of clinical outcomes, resource utilization, and effect modification.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a common complication in patients with cirrhosis and is associated with poor outcomes. However, contemporary national data quantifying the impact of AKI severity on mortality and healthcare utilization, as well as potential effect modification across patient subgroups, remain limited.
methodsWe conducted a retrospective cohort study using the 2023 Nationwide Inpatient Sample. Adult hospitalizations with cirrhosis were identified using ICD-10-CM codes. AKI was categorized as no AKI, non-dialysis-requiring AKI, and dialysis-requiring (AKI-D). Survey-weighted multivariable regression models evaluated associations between AKI and in-hospital mortality, length of stay (LOS), and hospital costs. Sensitivity analyses and interaction testing by age and chronic kidney disease (CKD) were performed.
resultsA total of 70,219 unweighted hospitalizations, representing approximately 351,095 nationally, were included. AKI occurred in 32.6% of hospitalizations. In-hospital mortality was higher among patients with AKI compared with those without AKI (13.0% vs. 2.5%, p < 0.001). In adjusted analyses, non-dialysis-requiring AKI was associated with increased mortality (adjusted odds ratio [OR] 4.34, 95% CI 3.99-4.72), while AKI-D was associated with markedly higher mortality (OR 16.37, 95% CI 14.18-18.91). AKI was also associated with increased LOS (ratio 1.45 for non-dialysis AKI; 2.78 for AKI-D) and higher hospital costs (ratio 1.43 and 3.75, respectively). Findings were consistent across multiple sensitivity analyses. Significant interactions were observed by CKD and age, with stronger relative effects in patients without CKD and in younger individuals (p for interaction < 0.001).
conclusionsAKI is common among hospitalized patients with cirrhosis and is strongly associated with increased mortality and healthcare utilization, with a clear graded relationship by severity. The impact of AKI varies across patient subgroups, highlighting the importance of individualized risk assessment. Strategies targeting early recognition and prevention of AKI may improve outcomes and reduce healthcare burden in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.